Farmas USA

Proximo meneico y las ACHN a 4,00 y AMRN podria tocar la base del canal por los 2,9bajos.

Ese gap XBI en 58 ...

MACK
Quién hubiera pillado esos $3.6 a los que ha llegado en PM... He añadido un paquetito a $4.42. La caída es exagerada.

Harto ya del asunto he puesto orden de venta A MERCADO de las PACB ... a las 21:58 ...

Pues nada ... sesion cerrada y que me voy a la cama con ellas .. cagon sos .. 2 minutos y no encontro contrapartida ??? pfffff

Mañana me haran la puñeta de abrir con gap down, lo estoy viendo .... 

ALXN

Ensayo sin resultados significativos

http://finance.yahoo.com/news/alexion-announces-top-line-results-210400096.html

IBB y XBI en diario respectivamente. Pues eso, soy oso.

AMGN no se atreve con ese gap, no hay manera ...

REGN, esta es un cachondeo 

Dejo para el proximo año las AMRN ... que se vaya rellenando el grafico ... a ver que pasa ... 

NVAX. Por arriba del MM50 bullish ... por abajo de la MM20 bearish, muy simple

HZNP

hay momentos que se aprecian mejor las cosas en minutajes inferiores, velas 30 min

Horizon Pharma plc Announces Availability of QUINSAIR(TM) (levofloxacin inhalation solution) in Canada for the Treatment of Specific Lung Infections in Adults with Cystic Fibrosis

DUBLIN, Ireland, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliate Horizon Therapeutics Canada Limited, today announced that QUINSAIR™ (levofloxacin inhalation solution) is now available in Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). QUINSAIR is the first inhaled fluoroquinolone antibiotic to receive marketing authorization from Health Canada.

"Prevalence of Pseudomonas aeruginosa is high among people with cystic fibrosis and chronic management is often required after a patient is infected with these bacteria," said Jared Rhines, vice president and general manager, Canada, LATAM and APAC, Horizon Pharma. "Horizon has a long-term commitment to people living with rare diseases, and we're looking forward to working with healthcare professionals and patient organizations that address the needs of the Canadian cystic fibrosis community at risk for these insidious infections."

CF is a rare, life-threatening genetic disease affecting approximately 75,000 people worldwide,1 and more than 4,100 people in Canada.2 It is the most common fatal genetic disease among Canadian young adults, and primarily affects the digestive system and lungs. While disease severity differs among people living with CF, persistent and ongoing infections in the lungs are the most frequent cause of death.3 Pseudomonas aeruginosa is one of the most common bacteria causing lung infections in people living with CF.4

"It is very important that healthcare professionals in Canada have access to a variety of medicines for people with cystic fibrosis dealing with Pseudomonas aeruginosa infections," said Norma Beauchamp, president and chief executive officer, Cystic Fibrosis Canada. "Once established in the airways, this bacteria becomes very difficult to eliminate, often requiring aggressive treatment with multiple therapies. QUINSAIR provides an inhaled option and we're pleased that it is now available in Canada."